Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT07872306Phase 2Not yet recruiting
- Sponsor
- Satellos Bioscience Inc.
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, randomised, double-blind trial of forazapadin in facioscapulohumeral muscular dystrophy (FSHD) (3 arms), sponsored by Satellos Bioscience Inc. Primary endpoints: Safety evaluation of forazapadin at 48 weeks and Efficacy of forazapadin as treatment at 48 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
forazapadin
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT07872306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872306.